BrainsWay (BWAY) Q3 2026 Earnings Call Transcript
BrainsWay reported Q3 2026 revenue growth of 34% YoY to $18.1M, with gross margin at 78%. RPO increased 31% to $85M. Clinical trials showed promise in reducing suicidal ideation and treating depression with Alzheimer's. SWIFT protocol gained reimbursement access for 70M lives. The company invested $3M in Radial Health and partnered with Inland Psychiatric Medical Group. Operating income rose 107% YoY to $2.6M, with net income up 42% to $2.2M.
How this was made
The 30-second read
Why it matters
Earnings beat and expanding RPO indicate a strengthening business model, but execution risk remains around new indications and reimbursement.
Market read
First report of BrainsWay's Q3 2026 financials provides fresh data for traders; strong growth may trigger short‑term buying pressure.
What to watch
Potential regulatory delays for new indications and reliance on reimbursement expansions could temper upside.
Background
BrainsWay provides Deep TMS therapy for depression and other mental health conditions; the company is expanding its SWIFT protocol and reimbursement coverage.
Ticker impact
Q3 2026 earnings call disclosed 34% revenue growth to $18.1M and 107% operating income increase, new financial metrics for BrainsWay.
likely upside as market prices in higher revenue and profit growth
First disclosure of quarterly results shows significant growth in revenue, gross profit, and operating income, indicating improved profitability and cash flow.
Market effects
Positive earnings may boost sentiment in the neurostimulation and mental health device sector.
Limited to U.S. small-cap investors; no broad regional effect.
Minimal global impact beyond niche biotech investors.
Counterpoint
Despite growth, the company remains small and cash‑burn heavy; valuation may still be stretched.
Key entities
- companyBrainsWay
Neurostimulation device maker reporting Q3 2026 results.
- companyRadial Health
Recipient of a $3M strategic minority investment by BrainsWay.
